Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
PD-1/PD-L1 Immunotherapy market report explains the definition, types, applications, major countries, and major players of the PD-1/PD-L1 Immunotherapy market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
AstraZeneca Plc
Merck & Co Inc
Eli Lilly & Company
GlaxoSmithKline plc
Regeneron Pharmaceuticals Inc
Novartis AG
Innovent Biologics Inc
BeiGene Ltd
F Hoffmann-La Roche Ltd
Pfizer Inc
Jiangsu HengRui Medicine Co Ltd
Sanofi SA
Bristol-Myers Squibb Company
Chia Tai Tianqing Pharmaceutical Group Co Ltd
By Type:
PD-1 Inhibitors
PD-L1 Inhibitors
By End-User:
Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global PD-1/PD-L1 Immunotherapy Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 PD-1/PD-L1 Immunotherapy Outlook to 2028- Original Forecasts
-
2.2 PD-1/PD-L1 Immunotherapy Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term PD-1/PD-L1 Immunotherapy Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global PD-1/PD-L1 Immunotherapy Market- Recent Developments
-
6.1 PD-1/PD-L1 Immunotherapy Market News and Developments
-
6.2 PD-1/PD-L1 Immunotherapy Market Deals Landscape
7 PD-1/PD-L1 Immunotherapy Raw Materials and Cost Structure Analysis
-
7.1 PD-1/PD-L1 Immunotherapy Key Raw Materials
-
7.2 PD-1/PD-L1 Immunotherapy Price Trend of Key Raw Materials
-
7.3 PD-1/PD-L1 Immunotherapy Key Suppliers of Raw Materials
-
7.4 PD-1/PD-L1 Immunotherapy Market Concentration Rate of Raw Materials
-
7.5 PD-1/PD-L1 Immunotherapy Cost Structure Analysis
-
7.5.1 PD-1/PD-L1 Immunotherapy Raw Materials Analysis
-
7.5.2 PD-1/PD-L1 Immunotherapy Labor Cost Analysis
-
7.5.3 PD-1/PD-L1 Immunotherapy Manufacturing Expenses Analysis
8 Global PD-1/PD-L1 Immunotherapy Import and Export Analysis (Top 10 Countries)
-
8.1 Global PD-1/PD-L1 Immunotherapy Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global PD-1/PD-L1 Immunotherapy Export by Region (Top 10 Countries) (2017-2028)
9 Global PD-1/PD-L1 Immunotherapy Market Outlook by Types and Applications to 2022
-
9.1 Global PD-1/PD-L1 Immunotherapy Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global PD-1 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.2 Global PD-L1 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global PD-1/PD-L1 Immunotherapy Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Non-Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Esophageal Cancer Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Hepatocellular Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise PD-1/PD-L1 Immunotherapy Market Analysis and Outlook till 2022
-
10.1 Global PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.2.2 Canada PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.2.3 Mexico PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.2 UK PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.3 Spain PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.4 Belgium PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.5 France PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.6 Italy PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.7 Denmark PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.8 Finland PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.9 Norway PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.10 Sweden PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.11 Poland PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.12 Russia PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.3.13 Turkey PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.2 Japan PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.3 India PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.4 South Korea PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.5 Pakistan PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.6 Bangladesh PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.7 Indonesia PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.8 Thailand PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.9 Singapore PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.10 Malaysia PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.11 Philippines PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.4.12 Vietnam PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.2 Colombia PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.3 Chile PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.4 Argentina PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.5 Venezuela PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.6 Peru PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.7 Puerto Rico PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.5.8 Ecuador PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.6.2 Kuwait PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.6.3 Oman PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.6.4 Qatar PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.6.5 Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.6.6 United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.7.2 South Africa PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.7.3 Egypt PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.7.4 Algeria PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
-
10.8.2 New Zealand PD-1/PD-L1 Immunotherapy Consumption (2017-2022)
11 Global PD-1/PD-L1 Immunotherapy Competitive Analysis
-
11.1 AstraZeneca Plc
-
11.1.1 AstraZeneca Plc Company Details
-
11.1.2 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.1.4 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Merck & Co Inc
-
11.2.1 Merck & Co Inc Company Details
-
11.2.2 Merck & Co Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Merck & Co Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.2.4 Merck & Co Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Eli Lilly & Company
-
11.3.1 Eli Lilly & Company Company Details
-
11.3.2 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.3.4 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 GlaxoSmithKline plc
-
11.4.1 GlaxoSmithKline plc Company Details
-
11.4.2 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.4.4 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Regeneron Pharmaceuticals Inc
-
11.5.1 Regeneron Pharmaceuticals Inc Company Details
-
11.5.2 Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.5.4 Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Novartis AG
-
11.6.1 Novartis AG Company Details
-
11.6.2 Novartis AG PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Novartis AG PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.6.4 Novartis AG PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Innovent Biologics Inc
-
11.7.1 Innovent Biologics Inc Company Details
-
11.7.2 Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.7.4 Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 BeiGene Ltd
-
11.8.1 BeiGene Ltd Company Details
-
11.8.2 BeiGene Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 BeiGene Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.8.4 BeiGene Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 F Hoffmann-La Roche Ltd
-
11.9.1 F Hoffmann-La Roche Ltd Company Details
-
11.9.2 F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.9.4 F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Pfizer Inc
-
11.10.1 Pfizer Inc Company Details
-
11.10.2 Pfizer Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Pfizer Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.10.4 Pfizer Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Jiangsu HengRui Medicine Co Ltd
-
11.11.1 Jiangsu HengRui Medicine Co Ltd Company Details
-
11.11.2 Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.11.4 Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Sanofi SA
-
11.12.1 Sanofi SA Company Details
-
11.12.2 Sanofi SA PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Sanofi SA PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.12.4 Sanofi SA PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Bristol-Myers Squibb Company
-
11.13.1 Bristol-Myers Squibb Company Company Details
-
11.13.2 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.13.4 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Chia Tai Tianqing Pharmaceutical Group Co Ltd
-
11.14.1 Chia Tai Tianqing Pharmaceutical Group Co Ltd Company Details
-
11.14.2 Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
11.14.4 Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
11.14.5 Recent Research and Development Strategies
12 Global PD-1/PD-L1 Immunotherapy Market Outlook by Types and Applications to 2028
-
12.1 Global PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global PD-1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global PD-L1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Non-Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Esophageal Cancer Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Hepatocellular Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
12.2.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise PD-1/PD-L1 Immunotherapy Market Analysis and Outlook to 2028
-
13.1 Global PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.2.2 Canada PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.2.3 Mexico PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.2 UK PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.3 Spain PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.4 Belgium PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.5 France PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.6 Italy PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.7 Denmark PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.8 Finland PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.9 Norway PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.10 Sweden PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.11 Poland PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.12 Russia PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.3.13 Turkey PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.2 Japan PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.3 India PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.4 South Korea PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.5 Pakistan PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.7 Indonesia PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.8 Thailand PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.9 Singapore PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.10 Malaysia PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.11 Philippines PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.4.12 Vietnam PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.2 Colombia PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.3 Chile PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.4 Argentina PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.5 Venezuela PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.6 Peru PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.5.8 Ecuador PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.6.2 Kuwait PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.6.3 Oman PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.6.4 Qatar PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.7.2 South Africa PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.7.3 Egypt PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.7.4 Algeria PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
-
13.8.2 New Zealand PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of PD-1/PD-L1 Immunotherapy
-
Figure of PD-1/PD-L1 Immunotherapy Picture
-
Table Global PD-1/PD-L1 Immunotherapy Import by Region (Top 10 Countries) (2017-2028)
-
Table Global PD-1/PD-L1 Immunotherapy Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global PD-1 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global PD-L1 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Esophageal Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Hepatocellular Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Table North America PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure United States PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Canada PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Mexico PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table Europe PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure Germany PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure UK PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Spain PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Belgium PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure France PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Italy PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Denmark PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Finland PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Norway PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Sweden PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Poland PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Russia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Turkey PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table APAC PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure China PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Japan PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure India PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure South Korea PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Pakistan PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Indonesia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Thailand PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Singapore PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Malaysia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Philippines PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Vietnam PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table South America PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure Brazil PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Colombia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Chile PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Argentina PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Venezuela PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Peru PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Ecuador PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table GCC PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure Bahrain PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Kuwait PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Oman PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Qatar PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table Africa PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure Nigeria PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure South Africa PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Egypt PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Algeria PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table Oceania PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)
-
Figure Australia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure New Zealand PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)
-
Table AstraZeneca Plc Company Details
-
Table AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Plc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Merck & Co Inc Company Details
-
Table Merck & Co Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Merck & Co Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Eli Lilly & Company Company Details
-
Table Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly & Company PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table GlaxoSmithKline plc Company Details
-
Table GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Regeneron Pharmaceuticals Inc Company Details
-
Table Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Novartis AG Company Details
-
Table Novartis AG PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Novartis AG PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Innovent Biologics Inc Company Details
-
Table Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table BeiGene Ltd Company Details
-
Table BeiGene Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table BeiGene Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table BeiGene Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table F Hoffmann-La Roche Ltd Company Details
-
Table F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Pfizer Inc Company Details
-
Table Pfizer Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Inc PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Pfizer Inc PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Jiangsu HengRui Medicine Co Ltd Company Details
-
Table Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Sanofi SA Company Details
-
Table Sanofi SA PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi SA PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Sanofi SA PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Bristol-Myers Squibb Company Company Details
-
Table Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product Portfolio
-
Table Chia Tai Tianqing Pharmaceutical Group Co Ltd Company Details
-
Table Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Main Business and Markets Served
-
Table Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Product Portfolio
-
Figure Global PD-1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PD-L1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Esophageal Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hepatocellular Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Table North America PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure United States PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure Germany PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure France PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure China PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure India PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Table South America PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure Brazil PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure Bahrain PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure Nigeria PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)
-
Figure Australia PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
